Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

计划入组 50 人 · 首次发布于 2026 年 3 月 6 日

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

计划入组 62 人 · 首次发布于 2024 年 9 月 19 日

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

计划入组 60 人 · 首次发布于 2026 年 5 月 6 日

Flotufolastat F-18(Posluma)

C₆₃H₉₉FN₁₂O₂₅Si

XTR020

180 Life Sciences

United States

Simcha Il 18, Inc.

United States

18F-Flotufolastat Shows High Detection Rate in Prostate Cancer Recurrence with Low PSA

Diuretic Protocol Enhances Prostate Cancer Detection in 18F-Flotufolastat PET/CT Imaging

FDA Approves Posluma, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer